NCT03558360

Brief Summary

Bariatric surgery is currently the only method that has proven long-term effectiveness in obesity. Although the benefit of physical activity on weight loss has been demonstrated, no correlation has ever been reported between preoperative lean body mass and postoperative weight loss. Dry lean mass is probably an essential prognostic factor for the effectiveness of bariatric surgery. The main objective of this study is to define a preoperative dry lean body mass threshold as a worst prognostic factor for weight loss one year after bariatric surgery. The management of patients included in this study was modelled on the management usually offered to patients followed for the same pathology in the diabeto-endocrinology department. There are no study-specific examinations that are not part of current practice.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
180

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Oct 2018

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 4, 2018

Completed
11 days until next milestone

First Posted

Study publicly available on registry

June 15, 2018

Completed
4 months until next milestone

Study Start

First participant enrolled

October 15, 2018

Completed
3.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2022

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2022

Completed
Last Updated

December 23, 2021

Status Verified

December 1, 2021

Enrollment Period

3.5 years

First QC Date

June 4, 2018

Last Update Submit

December 22, 2021

Conditions

Keywords

lean body massbariatric surgery

Outcome Measures

Primary Outcomes (1)

  • Measurement of dry lean mass in pre-operative by impedance measurement

    Excess weight loss at M12: ideal weight is defined in relation to height for a BMI of 25.0 kg/m2. Excess weight is the difference between the observed weight and the ideal weight. Excess weight loss is the ratio of weight loss to excess weight.

    12 months after bariatric surgery

Study Arms (1)

Bariatric surger

Bariatric surgery and impedance measurement

Diagnostic Test: Impedance measurement

Interventions

Impedance measurementDIAGNOSTIC_TEST

Measurement of dry lean body mass berfore bariatric surgery by impedance measurement.

Bariatric surger

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients presenting (or having presented since 2014) an obesity with a bariatric surgery project and followed by endocrinologist doctors.

You may qualify if:

  • BMI ≥ 40 or BMI ≥ 35 kg/m2 and a complication that can be improved after bariatric surgery: cardiovascular disease including hypertension, severe metabolic disorder including type 2 diabetes, sleep apnea syndrome or other severe respiratory disorder, hepatic steatosis, disabling osteoarticular disease.
  • Patient requiring bariatric surgery (sleeve-gastrectomy or gastric bypass)
  • Patient who has agreed to participate in the study
  • Patient with social security coverage.

You may not qualify if:

  • Patient with a contraindication to bariatric surgery (cognitive or psychological disorders, severe eating disorders, addiction to alcohol or psychoactive substances, contraindication to general anaesthesia, multiple history of digestive surgery, high risk of undernutrition (progressive cancer, chronic inflammatory bowel disease, cirrhosis, severe renal insufficiency...)
  • Pregnant or lactating women
  • Minor patient
  • Major patient under tutorship, curatorship, or deprived of liberty
  • Patient unable to understand protocol and / or give express consent
  • Patient not affiliated with a social security system or beneficiary of such a scheme
  • Patient participating in an intervention-type clinical research protocol likely to modify the evaluations of this protocol
  • adults under the protection of justice

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Centre Hospitalier Departemental Vendée

La Roche-sur-Yon, 85925, France

RECRUITING

Study Officials

  • Barbara FEIGEL-GUILLER, MD

    Centre Hospitalier Départemental Vendée

    STUDY DIRECTOR

Central Study Contacts

François ETCHEVERRIGARAY, PharmD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 4, 2018

First Posted

June 15, 2018

Study Start

October 15, 2018

Primary Completion

April 1, 2022

Study Completion

September 1, 2022

Last Updated

December 23, 2021

Record last verified: 2021-12

Locations